AIM:To search for further immunodominant peptides of the pyruvate dehydrogenase complex E2-component (PDC-E2) recognized by antimitochondrial antibodies (AMA) in primary biliary cirrhosis (PBC). METHODS:Sera from 95 p...AIM:To search for further immunodominant peptides of the pyruvate dehydrogenase complex E2-component (PDC-E2) recognized by antimitochondrial antibodies (AMA) in primary biliary cirrhosis (PBC). METHODS:Sera from 95 patients with PBC were tested by enzyme-linked immunosorbent assay against 33 synthetic overlapping peptides (25 amino acids; aa) covering the entire length of the E2-subunit of PDC-E2. Furthermore,the inner lipoyl peptide 167-184 was used in an unlip oylated and a lipoylated form as well as coupled to ovalbumin. Sera from 11 AMA negative/ANA posit ive PBC patients,63 patients with other liver disorders and 22 healthy blood donors served as controls.RESULTS:Of the 95 PBC-sera,74% reacted with the peptide 475-499 and 58% with the pept ide 407-431 located within the catalytic domain of PDC-E2. Patients with other disorders or healthy controls were positive in only up to 18%. Antibodies to the unlipoylatedand lip oylated pept ide 167-184 within the inner lipoyl domain were found in only 5% and 11% of the PBC sera,respectively; using ovalbumin-coupled peptides,the incidence increased up to 57% (unlipoylated form). CONCLUSION:Peptides within the catalytic site of PDC-E2 rather than the previously reported lipoyl binding peptide 167-184 may represent major immunodomin ant epitopes recognized by AMA in PBC.展开更多
After preparing the EU^3＋-doped scheelite nano-material by Pechini method with the nanoparticles of 30-50 nm in diameter, X-ray diffraction （XRD）, transmission electron microscopy （TEM） and high resolution transm...After preparing the EU^3＋-doped scheelite nano-material by Pechini method with the nanoparticles of 30-50 nm in diameter, X-ray diffraction （XRD）, transmission electron microscopy （TEM） and high resolution transmission electron microscopy （HRTEM） were used to show a microcosmic description of the particle morphology and crystal structure. The spectrum signature of the nano-scheelite, which was taken by fluorescence spectrometer, was used to discuss the difference of luminescent performance between the nano-scheelite and bulk scheelite. The atomic site of the nano-scheelite was intuitively shown through HRTEM images and HRTEM simulated images from the relation between luminescent properties and crystal structure, which was analyzed by spectrum probe. The results of antitumor activity examined by the 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide （MTT） method show that the inhibition of human promyelocytic leukemia cell line （HL60） is enhanced immediately with increasing the concentration and presents a reliance on the quantity. The results of fluorescence spectra and structure show that the antitumor activity has something to do with micro-structure and surface charge.展开更多
文摘AIM:To search for further immunodominant peptides of the pyruvate dehydrogenase complex E2-component (PDC-E2) recognized by antimitochondrial antibodies (AMA) in primary biliary cirrhosis (PBC). METHODS:Sera from 95 patients with PBC were tested by enzyme-linked immunosorbent assay against 33 synthetic overlapping peptides (25 amino acids; aa) covering the entire length of the E2-subunit of PDC-E2. Furthermore,the inner lipoyl peptide 167-184 was used in an unlip oylated and a lipoylated form as well as coupled to ovalbumin. Sera from 11 AMA negative/ANA posit ive PBC patients,63 patients with other liver disorders and 22 healthy blood donors served as controls.RESULTS:Of the 95 PBC-sera,74% reacted with the peptide 475-499 and 58% with the pept ide 407-431 located within the catalytic domain of PDC-E2. Patients with other disorders or healthy controls were positive in only up to 18%. Antibodies to the unlipoylatedand lip oylated pept ide 167-184 within the inner lipoyl domain were found in only 5% and 11% of the PBC sera,respectively; using ovalbumin-coupled peptides,the incidence increased up to 57% (unlipoylated form). CONCLUSION:Peptides within the catalytic site of PDC-E2 rather than the previously reported lipoyl binding peptide 167-184 may represent major immunodomin ant epitopes recognized by AMA in PBC.
基金supported by the National Natural Science Foundation of China(No.40072013)
文摘After preparing the EU^3＋-doped scheelite nano-material by Pechini method with the nanoparticles of 30-50 nm in diameter, X-ray diffraction （XRD）, transmission electron microscopy （TEM） and high resolution transmission electron microscopy （HRTEM） were used to show a microcosmic description of the particle morphology and crystal structure. The spectrum signature of the nano-scheelite, which was taken by fluorescence spectrometer, was used to discuss the difference of luminescent performance between the nano-scheelite and bulk scheelite. The atomic site of the nano-scheelite was intuitively shown through HRTEM images and HRTEM simulated images from the relation between luminescent properties and crystal structure, which was analyzed by spectrum probe. The results of antitumor activity examined by the 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide （MTT） method show that the inhibition of human promyelocytic leukemia cell line （HL60） is enhanced immediately with increasing the concentration and presents a reliance on the quantity. The results of fluorescence spectra and structure show that the antitumor activity has something to do with micro-structure and surface charge.
